First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453100, China.
J Interv Cardiol. 2023 Jun 26;2023:5210808. doi: 10.1155/2023/5210808. eCollection 2023.
According to the latest coronary interventional guidelines, a drug-eluting stent is the recommended reperfusion therapy in primary percutaneous coronary intervention (pPCI). However, deficiencies and defects, such as in-stent restenosis (ISR), incomplete stent apposition, stent thrombosis, reinfarction after stent implantation, long-term dual antiplatelet drug use, and adverse reactions of metal implants, plague clinicians and patients. Drug-coated balloon (DCB), which delivers antiproliferative agents into the vessel wall without stent implantation and leaves no implants behind after the procedure, is a novel option for percutaneous coronary intervention and has proven to be a promising strategy in cases of ISR, small vessel coronary artery disease, and bifurcation lesions. However, most of the available experience has been gained in elective percutaneous coronary intervention, and experience in pPCI is lacking. The current evidence for the use of DCB-only in pPCI was discussed and analyzed in this review.
根据最新的冠状动脉介入治疗指南，药物洗脱支架是经皮冠状动脉介入治疗（pPCI）的推荐再灌注治疗方法。然而，支架内再狭窄（ISR）、支架贴壁不良、支架内血栓形成、支架植入后再梗死、长期双联抗血小板药物应用以及金属植入物的不良反应等缺陷和不足困扰着临床医生和患者。药物涂层球囊（DCB）在不植入支架的情况下将抗增殖药物输送到血管壁中，并且在手术后不会留下任何植入物，是经皮冠状动脉介入治疗的一种新选择，并且在 ISR、小血管冠状动脉疾病和分叉病变中已被证明是一种很有前途的策略。然而，大多数可用的经验都来自选择性经皮冠状动脉介入治疗，在 pPCI 中的经验还很缺乏。本综述讨论和分析了仅使用 DCB 在 pPCI 中的应用证据。
